BioCryst to Present at 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 9:45 a.m. ET. The event will be conducted virtually, allowing investors to listen via a live audio webcast. BioCryst focuses on developing novel, oral medicines for rare diseases, with products like ORLADEYO® and RAPIVAB® already approved in various regions. The company is also advancing programs for several treatments targeting specific diseases. For more details, visit www.biocryst.com.

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 40^th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Monday, January 10, 2022 at 9:45 a.m. ET.

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When is BioCryst Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

BioCryst Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 10, 2022, at 9:45 a.m. ET.

Where can I access the presentation by BioCryst Pharmaceuticals?

The presentation can be accessed through a live audio webcast in the Investors section of BioCryst's website.

What is BioCryst Pharmaceuticals known for?

BioCryst Pharmaceuticals specializes in developing oral medicines for rare diseases, including ORLADEYO® and RAPIVAB®.

What treatments is BioCryst Pharmaceuticals currently developing?

BioCryst is developing treatments like BCX9930 for complement-mediated diseases and BCX9250 for fibrodysplasia ossificans progressiva.

What is the ticker symbol for BioCryst Pharmaceuticals?

The ticker symbol for BioCryst Pharmaceuticals is BCRX.